The antitumour drug ABTL0812 impairs neuroblastoma growth through endoplasmic reticulum stress-mediated autophagy and apoptosis

• DOI: 10.1038/s41419-020-02986-w
• Publication Date: 2020-09-17T21:38:34Z
• Authors: Laia París-Coderch; Aroa Soriano; Carlos Jiménez; Tatiana Erazo; Pau Muñoz-Guardiola; Marc Masanas; Roberta Antonelli; Ariadna Boloix; José Alfón; Héctor Pérez-Montoyo; Marc Yeste-Velasco; Carles Domènech; Josep Roma; Josep Sánchez de ...; Lucas Moreno; José M. Lizcano; Soledad Gallego; Miguel F. Segura
• Keywords: Drug development; Antineoplastic Agents; Apoptosis; Endoplasmic Reticulum; Article; Paediatric cancer; Inhibitory Concentration 50; Mice; Neuroblastoma; 03 medical and health sciences; Drug Development; Cell Line, Tumor; Autophagy; Animals; Humans; Isotretinoin; Cell Proliferation; 0303 health sciences; Endoplasmic Reticulum Stress; 3. Good health; Pancreatic Neoplasms; Linoleic Acids; Unfolded Protein Response; Female; Neoplasm Transplantation; DNA Damage

AbstractNeuroblastoma is the leading cause of cancer death in children aged 1 to 4 years. Particularly, five-year overall survival for high-risk neuroblastoma is below 50% with no curative options when refractory or relapsed. Most of current therapies target cell division and proliferation, thereby inducing DNA damage and programmed cell death. However, aggressive tumours often present alterations of these processes and are resistant to therapy. Therefore, exploring alternative pathways to induce tumour cell death will provide new therapeutic opportunities for these patients. In this study we aimed at testing the therapeutic potential of ABTL0812, a novel anticancer drug that induces cytotoxic autophagy to eliminate cancer cells, which is currently in phase II clinical trials of adult tumours. Here, we show that ABTL0812 impaired the viability of clinical representative neuroblastoma cell lines regardless of genetic alterations associated to bad prognosis and resistance to therapy. Oral administration of ABTL0812 to mice bearing neuroblastoma xenografts impaired tumour growth. Furthermore, our findings revealed that, in neuroblastoma, ABTL0812 induced cancer cell death via induction of endoplasmic reticulum stress, activation of the unfolded protein response, autophagy and apoptosis. Remarkably, ABTL0812 potentiated the antitumour activity of chemotherapies and differentiating agents such as irinotecan and 13-cis-retinoic acid. In conclusion, ABTL0812 distinctive mechanism of action makes it standout to be used alone or in combination in high-risk neuroblastoma patients.